The present invention relates to a compound represented by the following formula I or a pharmaceutically acceptable salt thereof; wherein R
1
, R
2
, and y are defined herein. The present invention further relates to compositions that include the compound of the present invention as well as a method of treating a patient from endometreosis or uterine fibroids.
Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists
作者:Scott K. Thompson、David G. Washburn、James S. Frazee、Kevin P. Madauss、Tram H. Hoang、Leahann Lapinski、Eugene T. Grygielko、Lindsay E. Glace、Walter Trizna、Shawn P. Williams、Chaya Duraiswami、Jeffrey D. Bray、Nicholas J. Laping
DOI:10.1016/j.bmcl.2009.06.055
日期:2009.8
progesterone receptor (PR) partial agonist bound to the PR ligand binding domain, a novel PR partial agonistclass containing a pyrrolidine ring was designed. Members of this class of N-alkylpyrrolidines demonstrate potent and highlyselective partial agonism of the progesterone receptor, and one of these analogs was shown to be efficacious upon oral dosing in the OVX rat model of estrogen opposition